Adcetris Earns Orphan Drug Status for Mycosis Fungoides


Seattle Genetics, makers of the anti-CD30 treatment Adcetris for Hodgkin's lymphoma and anaplastic large cell lymphoma announced last week that the company has secured orphan drug status for Adcetris for a new indication.

The indication is for the cutaneous T-cell lymphoma mycosis fungoides (MF), the most commonly diagnosed cutaneous T-cell lymphoma. Orphan drug status means that if the U.S. Food and Drug Administration eventually approves Adcetris for MF, the agency will not approve other similar products for MF for seven years, granting the company market exclusivity.

Seattle Genetics has been working to find a broader market for Adcetris, and clearly this move is another step in that direction.

Source: Business Week

LymphomaInfo Social